Fundamental Analysis of ALIGOS THERAPEUTICS INC(NASDAQ:ALGS) stock

Fundamental Rating

ALGS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. The financial health of ALGS is average, but there are quite some concerns on its profitability. ALGS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGS has reported negative net income.

In the past year ALGS has reported a negative cash flow from operations.

ALGS had negative earnings in each of the past 5 years.

In the past 5 years ALGS always reported negative operating cash flow.

1.2 Ratios

ALGS has a Return On Assets of -69.60%. This is in the lower half of the industry: ALGS underperforms 65.78% of its industry peers.

With a Return On Equity value of -112.65%, ALGS perfoms like the industry average, outperforming 42.07% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-69.6%
ROE	-112.65%
ROIC	N/A

ROA(3y)-59.28%

ROA(5y)-50.89%

ROE(3y)-85.72%

ROE(5y)-70.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALGS has less shares outstanding

ALGS has less shares outstanding than it did 5 years ago.

ALGS has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.58, we must say that ALGS is in the distress zone and has some risk of bankruptcy.

ALGS has a Altman-Z score of -7.58. This is in the lower half of the industry: ALGS underperforms 70.94% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that ALGS is not too dependend on debt financing.

ALGS has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.58

ROIC/WACCN/A

WACC10.39%

2.3 Liquidity

ALGS has a Current Ratio of 4.23. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ALGS (4.23) is comparable to the rest of the industry.

ALGS has a Quick Ratio of 4.23. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.

ALGS has a Quick ratio (4.23) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.23
Quick Ratio	4.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.77%, which is quite impressive.

ALGS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.64%.

EPS 1Y (TTM)71.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70.05%

Revenue 1Y (TTM)11.64%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-60.82%

3.2 Future

ALGS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.86% yearly.

Based on estimates for the next years, ALGS will show a very strong growth in Revenue. The Revenue will grow by 75.34% on average per year.

EPS Next Y82.77%

EPS Next 2Y30.53%

EPS Next 3Y17.83%

EPS Next 5Y14.86%

Revenue Next Year-76.96%

Revenue Next 2Y-69.6%

Revenue Next 3Y-25.99%

Revenue Next 5Y75.34%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALGS's earnings are expected to grow with 17.83% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.53%

EPS Next 3Y17.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALGS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (11/15/2024, 8:00:00 PM)

After market: 19.4 +0.23 (+1.2%)

19.17

-0.29 (-1.49%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap68.82M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-69.6%
ROE	-112.65%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.23
Quick Ratio	4.23
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)71.77%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y82.77%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)11.64%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ALIGOS THERAPEUTICS INC (ALGS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens